Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 5
Submit an article Journal homepage
186
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy

Shunzong YuanDepartment of Lymphoma, Head and Neck Cancer, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing, PR China; Correspondence[email protected]
,
Jianhua YuComprehensive Cancer Center, Division of Hematology, The James Cancer Hospital, The Ohio State University, Columbus, OH, USA
,
Brad HaverkosComprehensive Cancer Center, Division of Hematology, The James Cancer Hospital, The Ohio State University, Columbus, OH, USA
&
Hang SuDepartment of Lymphoma, Head and Neck Cancer, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing, PR China;
Pages 1194-1196 | Received 10 Apr 2015, Accepted 19 May 2015, Published online: 06 Jan 2016

References

  • Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11:1573–1582.
  • Dong M, Ning ZQ, Xing PY, et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012;69:1413–1422.
  • Ordemann R, Stohlmacher J, Beuthien-Baumann B, et al. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol. 2013;92:125–127.
  • Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–480.
  • Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28:3987–3993.
  • Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–465.
  • Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–436.
  • Ferreri AJ, Govi S, Pileri SA, et al. Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol. 2012;83:293–302.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.